Drug-induced diabetes mellitus: The exemple of atypical antipsychotics;Diabète sucré iatrogène: L'exemple des anti-psychotiques atypiques

Revue Medicale de Liege

Volumn 60, Issue 5-6, 2005, Pages 455-460

  Scheen, A J ^a,c   De Hert, M ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c CHU SART TILMAN   (Belgium)

Author keywords

Atypical antipsychotics; Diabetes mellitus; Ketoacidosis; Metabolic syndrome; Obesity; Pancreatitis

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; KETOACIDOSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; REVIEW; RISK FACTOR; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS; HUMANS; IATROGENIC DISEASE; INSULIN; INSULIN RESISTANCE; PANCREATITIS; RISK FACTORS; WEIGHT GAIN;

EID: 21744444629     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Scheen AJ.- Médicaments et diabète sucré. In: Reconnaître, comprendre, traiter le diabète sucré. 2e édition. JPh Assal, JM Ekoe, P Lefèbvre, G Slama (eds). EDISEM, Québec - Maloine, Paris, 1994, 257-264.
2. Scheen AJ, De Hert M.- Risque de diabète sucré sous antipsychotiques atypiques. Med Hyg, 2004, 62, 1591-1596.
3. American Diabètes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity.- Consensus Development Conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 2004, 27, 596-601.
4. De Nayer A, De Hert M, Scheen A, et al.- Belgian consensus on metabolic problems associated with second generation antipsychotics. Int J Psychiatry Clin Pract, 2005, in press.
5. Freedman R.- Drug Therapy. Schizophrenia. N Engl J Med, 2003, 349, 1738-1749.
6. Reynolds GP.- What is an atypical antipsychotic? J Psychopharmacol, 1997, 11, 195-199.
7. Newcomer JW- Metabolic risk during antipsychotic treatment. Clin Ther, 2004, 26, 1936-1946.
8. Melkersson K, Dahl M-L.- Adverse metabolic effects associated with atypical antipsychotics. Literature review and clinical implications. Drugs, 2004, 64, 701-723.
9. Baptista T, Kin NMKN, Beaulieu S, de Baptista EA.-Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry, 2002, 35, 205-219.
10. Ananth J, Venkatesh R, Burgoyne K, Gunatilake S.- Atypical antipsychotic drug use and diabetes. Psychother Psychosom, 2002, 71, 244-254.
11. Henderson DC.- Atypical antipsychotic-induced diabetes mellitus. How strong is the evidence? CNS Drugs, 2002, 16, 77-89.
12. Hedenmalm K, Hägg S, Stahl M, et al.- Glucose intolerance with atypical antipsychotics. Drug Safety, 2002, 25, 1107-1116.
13. Clark C, Burge MR.- Diabetes mellitus associated with atypical anti-psychotic medications. Diabetes Technol Ther, 2003, 5, 669-683.
14. Lean MEJ., Pajonk F-G. - Patients on atypical antipsychotic drugs. Another high-risk group for type 2 diabetes. Diabetes Care, 2003, 26, 1597-1605.
15. Kohen D.- Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry, 2004, 184 (Suppl 47), S64-66.
16. Caro JJ, Ward A, Levinton C, Robinson K.- The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry, 2002, 63, 1135-1139.
17. Gianfrancesco F, White R, Wang RH, Nasrallah HA.- Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol, 2003, 23, 328-335.
18. Sernyak MJ, Leslie DL, Alarcon RD, et al.- Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry, 2002, 159, 561-566.
19. Koro CE, Fedder DO, L'Italien GJ, et al.- Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ, 2002, 325, 243-245.
20. Wilson R, Souza L, Sarkar N, et al.- New-onset diabetes and ketoacidosis with atypical antipsychotics. Schiz Research, 2002, 59, 1-6.
21. Koller E, Schneider B, Bennett K, Dubitsky G.- Clozapine-associated diabetes. Am J Med, 2001, 111, 716-723.
22. Koller EA, Doraiswamy PM.- Olanzapine-associated diabetes mellitus. Pharmacotherapy, 2002, 22, 841-852.
23. Koller EA, Cross JT, Doraiswamy PM, Schneider BS.- Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy, 2003, 23, 735-744.
24. Koller EA, Weber J, Doraiswamy PM, Schneider BS.-A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry, 2004, 65, 857-863.
25. Koller EA, Cross JT, Doraiswamy PM, Malozowski SN.- Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's Med-Watch surveillance system and published reports. Pharmacotherapy, 2003, 23, 1123-1130.
26. Scheen AJ.- Current management of coexisting obesity and type 2 diabetes. Drugs, 2003, 63, 1165-1184.
27. Scheen AJ.- Pathophysiology of type 2 diabetes. Acta Clin Belg, 2003, 58, 335-341.
28. Ader M, Kim SP, Catalano KJ, et al.- Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease. A placebo-controlled study of olanzapine and risperidone in dogs. Diabetes, 2005, 54, 862-871.
29. De Hert M, Van Eyck D, Hermans G, et al.- Oral glucose tolerance test in schizophrenic patients treated with antipsychotics (abstract). Int J Neuropsychopharmacol, 2004, 7(Suppl 1), S424.
30. Luyckx FH, Scheen AJ.- Comment j'explore ... la controverse à propos de la place de l'hyperglycémie provoquée par voie orale en clinique. Rev Med Liège, 2003, 58, 701-705.
31. Ryan MC, Thakore JH.- Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sciences, 2002, 71, 239-257.
32. Casey DE, Haupt DW, Newcomer JW, et al.- Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004, 65 (Suppl 7), 4-18.
33. Nasrallah HA, Newcomer JW.- Atypical antipsychotics and metabolic dysregulation. Evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol, 2004, 24 (Suppl 1), S7-S14.
34. Chue P, Kovacs CS.- Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. Bipolar Disord, 2003, 5 (Suppl 2), 62-79.
35. Marder SR, Essock SM, Miller AL, et al.- Physical health monitoring of patients with schizophrenia. Am J Psychiatry, 2004, 161, 1334-1349.
36. Gough S, Pelever R.- Diabetes and its prevention: pragmatic solutions for people with schizophrenia. Br J Psychiatr, 2004, 184, S106-S111.